Oxiracetam in the treatment of multi-infarct dementia

Barry Baumel, Larry Eisner, Michael Karukin, Rosemary Macnamara, Richard J. Katz, Joseph Deveaugh-Geiss

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


1. 1. Initial clinical trials in approximately 200 patients with dementias of diverse etiology suggested that oxiracetam, a structural analogue of the nootropic piracetam, was of some benefit in the treatment of cognitive dysfunction. 2. 2. Because previous studies had not specifically examined the effects of oxiracetam upon dementias of vascular origin, the present study evaluated the therapeutic efficacy and safety of oxiracetam in the treatment of symptoms of multi-infarct dementia (MID) of Bild to moderate severity. 3. 3. Incremental doses of up to 1200 mg oxiracetam daily were tested in a dose-range finding design in a group of patients with clinically and neuropsychologically confirmed MID. 4. 4. Based on improvement in global evaluations of clinical change, our analysis suggests that the drug may be of some benefit in MID.

Original languageEnglish (US)
Pages (from-to)673-682
Number of pages10
JournalProgress in Neuropsychopharmacology and Biological Psychiatry
Issue number5
StatePublished - 1989
Externally publishedYes


  • dementia
  • multi-infarct dementia
  • nootropic
  • oxiracetam

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry


Dive into the research topics of 'Oxiracetam in the treatment of multi-infarct dementia'. Together they form a unique fingerprint.

Cite this